Other innovations
If your innovation doesn’t fit any of the active categories then this is the place to submit your innovation for feedback and the opportunity for wider adoption across the region.

Ideas (Publish, Detailed Submission)

Innovation 'Elevator Pitch':
Consultant Connect enables a GP to dial a single number to immediately reach an appropriate specialist.  Immediate Advice and Guidance is better for patients, clinicians & NHS. It is currently used in Elective, Urgent & Mental Health care settings.
Overview of Innovation:
Consultant Connect www.consultantconnect.org.uk is a simple CCG funded telecoms system that provides GPs with immediate access to telephone-based specialty mental health advice and guidance. By talking to a specialist, often whilst the patient is still in the surgery, the GP is better able to provide the right care first time to the patient, often avoiding an unnecessary referral or admission.  The specialist is based within a nearby NHS Trust Hospital.
 
GP calls connect directly, via a standard rate number, to teams of local specialists via their mobile phones with each specialist getting c 20 seconds to answer a call before it automatically forwards on to the next specialist. By connecting to teams of specialists, rather than to individuals, the connection rates are high.  The order in which specialists receive calls is based on a Rota of specialist availability that has been provided by the team. This rota can be either managed by us or by the team itself through an online portal.  The team of specialists are based in the local NHS Trusts.
 
Once connected, calls are recorded as highly encrypted, information-governed digital files which provide a medico-legal record which is available to the relevant GP practice and specialist team.  At the end of the call GPs are asked to stay on the line for a few seconds to rank the outcome – this gives the CCG a broad view as to the effectiveness of the system and their investment in it. Specialists are also asked to rank the outcome via text message as a back-up.
 
This service is in operation nationally across many specialties in physical and mental health.

In what instances should/can Consultant Connect be used?
The way in which this system is used is ultimately determined by the CCGs, Trust/Specialists and GP practices collectively, but it is generally accepted that calls will be made for patient-specific advice.
 
Within mental health we can connect GPs to the most appropriate mental health clinical professional (e.g. Psychiatrist, Psychologist, Cognitive Behavioural Therapist) to discuss issues such as:
  • Whether a referral is needed
  • Medication management/prescribing questions
  • Access to crisis support
We offer our service to best meet local needs between service users, GPs and Mental Health Trusts. 
 
We can tailor by service, specialty or pathway.
The speed of connection is such that the GP’s can (at their discretion) call whilst a patient is still with them.

Consultant Connect Service
https://www.youtube.com/watch?v=QWmNUubMCAE
 
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Mental Health: recovery, crisis and prevention / Long term conditions: a whole system, person-centred approach / Wellness and prevention of illness / Education, training and future workforce / Wealth creation / Digital health / Innovation and adoption / Patient and medicines safety / Person centred care
Benefit to NHS:
Why Trusts and CCGs work with us
  • Better patient experience – speeds up the care pathway, avoidance of unnecessary visits and contact with secondary care services, reductions in follow-up visits to GP Practices
  • Better GP experience – more patient episodes conclude with no follow-up work, case based learning, reconnecting with specialists
  • Better specialist experience – reduction in inappropriate referrals to secondary care services, reduction in the number of written requests for advice that require responses, reconnecting with GPs
  • Better for the mental health trust and CCG – full tracking of Advice & Guidance activity, greater ‘whole system’ efficiency, with savings available to support other hospital and community initiatives

How we perform
  • In Physical Health, across all elective care specialties, 66% of calls to Consultant Connect result in the patient avoiding a trip to hospital (referral or admission)
     
  • In Physical Health, across all of urgent care specialties, 27% of calls avoid a hospital trip that day (attendance or admission) and a further 36% of from A&E
     
  • In Mental Health, 39% of calls to our Mental Health Advice & Guidance line avoided a referral
 
What a Consultant Connect call has meant to …
… GPs
“The call enabled me to deal with some abnormal results in an efficient manner – which tests to request and what to do with the results. Saved a referral.”

… Consultants
“I took a call regarding a patient with syncope and ataxia. I avoided an unnecessary admission and got the lady seen urgently in an outpatient clinic.”

… Commissioners
“Consultant Connect is our only QIPP scheme that is over delivering against its YTD QIPP target. I’m genuinely struggling to know how to deal with all this positivity. It’s very unusual in my line of work. Great news.”
 
Testimonials:
https://www.youtube.com/watch?v=vEu7QDT4PzI
 
Initial Review Rating
4.80 (2 ratings)
Benefit to WM population:
Nearly 2,000 patients were spared an avoidable visit to hospital in the West Midlands by GPs who used Consultant Connect to contact specialists for immediate advice.
 
Doctors in the West Midlands turned to Consultant Connect, which allows them to speak to a specialist, often with the patient still in the room and can save them waiting days for a response or being sent to hospital for further checks.
 
Around 1,850 patients were spared going to Sandwell Hospital as well as Heartland and Good Hope Hospitals in Birmingham.
 
The service covers cardiology, diabetes and endocrinology, gastroenterology, gynaecology, general surgery, haematology, paediatrics, renal medicine, urology and respiratory medicine.
 
Since the phone line launched, GPs from 100 surgeries across Walsall, Sandwell and Solihull have made nearly 2,500 calls to specialists to get expert advice on the best care for their patients.
 
Consultant Connect estimates that West Midlands GPs and consultants have saved the NHS £570,000 by ensuring patients get the right treatment from the beginning.
 
When local GPs used Consultant Connect, around 50 per cent of their patients avoided the inconvenience of a trip to hospital.
 
Ref: Pharmacy Choice, 9 June, 2017
https://www.pharmacychoice.com/news/article.cfm?Article_ID=1832970
In one West Midlands CCG, the number of outpatient referrals dropped by 6 per cent over a three-month period.   This was Solihull CCG into HEFT (Heart of England Foundation Trust). 
https://www.consultantconnect.org.uk/breaking-news-ccg-establishes-consultant-connect-responsible-for-6-dip-in-referrals

We are currently working with the following CCGs in the West Midlands AHSN area:
 
Solihull CCG, Coventry and Rugby CCG, South Warwickshire CCG, North Warwickshire CCG, Worcestershire (South Worcestershire CCG, Redditch and Bromsgrove CCG and Wyre Forest CCG).  We are also working with the GP Federation Modality Partners in Sandwell.
 
We are working with the following Trusts:
  • HEFT - Heart of England NHS FT
  • SWFT - South Warwickshire NHS FT
  • UHCW - University Hospitals Coventry and Warwickshire NHS Trust
  • WAHT - Worcester Acute Hospitals NHS Trust
  • Sandwell and West Birmingham Hospitals NHS Trust - SWBH
  • George Eliot Hospital (GEH)
Current and planned activity: 
Current activity:
We are delivering Consultant Connect with over 45 CCGs across the UK, covering more than 12.8 million patients and over 1,700 GP practices.  To date we have handled 98,000 calls.

Planned/Required activity:
We would like to further roll out Consultant Connect to willing GPs and Trusts.  We would also appreciate any assistance in undertaking a formal return on investment review of our service to show very clear and robust data that we save money, and quickly.
 
What is the intellectual property status of your innovation?:
Consultant Connect Ltd own the telecoms system software and BI data reporting.
Return on Investment (£ Value): 
Very high
Return on Investment (Timescale): 
0-6 mon
Ease of scalability: 
Simple
Read more
Hide details
Jenny Welling-Palmer 15/02/2018 - 14:38 Publish 1 comment
6
1
Votes
-99999
Innovation 'Elevator Pitch':
NATROX® Oxygen Wound Therapy is a medical device designed to heal complex non-healing wounds to improve healing outcomes and quality of life, optimise clinical and economic resources, and reduce diabetic foot related amputation rates.
Overview of Innovation:
NATROX® Oxygen Wound Therapy is a portable, lightweight and easy to use patient-friendly device, designed to topically deliver continuous pure humidified oxygen to the wound bed. The device was developed in order to help improve healing outcomes in wounds which traditionally remain static due to wound hypoxia (oxygen starvation), a common symptom of diabetic and vascular issues.

The NATROX® system is comprised of an Oxygen Generator, 2 rechargeable batteries and a single-use disposable Oxygen Delivery System.  The therapy is designed to be used 24/7 and as an adjunct to standard of care, such as absorbent wound dressings, with an average therapy length of 12 weeks. The product is supported by a growing portfolio of clinical evidence, including RCT-level data, which has demonstrated a significant increase in the healing rates of complex and non-healing wounds, compared to standard of care alone (90% healing with NATROX®  vs 30% for standard of care).
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Innovation and adoption / Person centred care
Benefit to NHS:
It has been shown that over £5.3bn is spent by the NHS each year on the management of 2.2m wounds. The management of non-healing wounds accounts for a significant amount of NHS resources (approx. £3.1bn per year) and is increasing due to an ageing population and higher rates of diabetes and diabetic foot ulceration.  NATROX® therapy is designed to positively impact healing rates and thereby optimise both clinical and economic resources used on non-healing wounds, in turn helping clinicians and financial decision-makers to access and treat a greater number of patients.

Furthermore, it is well documented that patient quality of life is negatively impacted by having a wound, and especially a non-healing wound, with increases in social isolation and depression across this patient population. NATROX® therapy focuses on healing wounds which are unable to heal with standard treatments alone, as these treatments are unable to address the underlying causes of non-healing wounds, such as oxygen starvation (hypoxia). The therapy system therefore focuses on providing pure humidified oxygen to hypoxic wounds, whilst being comfortable, quiet, lightweight and easy-to-use for the patient, allowing normal mobility without any negative impact from the device.
Initial Review Rating
5.00 (1 ratings)
Benefit to WM population:
Increases in diabetes rates across the UK has in turn led to an increase in prevalence rates for diabetic foot disease and associated ulcers.  Furthermore, latest health economic evidence (e.g. Guest et al 2015 & 2017) has shown that non-healing wounds account for approximnately 57% of wounds at any time are deemed non-healing, which has a direct impact clinically, financially and to the patient experience.  Both minor and major amputation rates are increasing as a result due to the complexity of many diabetic foot ulcers, which has a significant impact on the health and wellbeing of these patients, with increased patient mortality following amputations of around 50% within 2 years.

Like many areas, the West Midlands is experiencing increased amputation rates, as a result of rising diabetes and diabetic foot ulcer prevalence.  This has a significant impact on the local health economy in the West Midlands area, especially in higher population bases such as city areas and surrounds.  Therefore, the adoption of NATROX® therapy across the West Midlands area could have a significant effect on helping to reduce non-healing levels within the diabetic foot ulcer population, and therefore positively impact the well documented clinical and economic cost that the burden of non-healing wounds brings with it.  

A resulting increased resource utilisation would allow a wider focus on the growing population of diabetic foot ulcer patients, improving clinical and economic output across local vascular, podiatry and wound management services.   
Current and planned activity: 
Inotec AMD is currently engaged with a variety of clinicians and decision-makers across the UK.  There are a number of local product evaluations active or soon to start, which will aim to demonstrate product afficacy in order to facilitate adoption of the technology locally and nationally.  in addition, a large NHS funded UK-based RCT is underway, which is due to report later in 2018.

Furthermore, the product is being reviewed both clinically and evidentially on a national level in both Scotland and Wales, where we are about to start a national clinical evaluation in Wales across both Welsh Podiatry and Tissue Viability networks, whilst in Scotland NATROX® therapy is being formally assessed by Health Improvement Scotland and the Scottish Health Technologies Group, in order to gain an official recommendation. 
What is the intellectual property status of your innovation?:
The intellectual property surrounding NATROX® therapy is owned by Inotec AMD Ltd.
Return on Investment (£ Value): 
Very high
Return on Investment (Timescale): 
0-6 mon
Ease of scalability: 
Simple
Regional Scalability:
NATROX® Oxygen Wound Therapy is not yet adopted at scale within the UK, but is undergoing product evaluations with a view to contract listings and wider adoption.  A programme of marketing and events is planned to support the wider awareness and adoption of the technology.
Measures:
Further clinical efficacy demonstrated through local and national product evaluations, health efficiency data supported by the NATROX® Health Efficiency Model utilising local clinical data and outcomes, patient quality of life data from local and national product evaluations, and usability info from clinical usage.
Adoption target:
Availability of NATROX® Oxygen Wound Therapy on podiatry, vascular and tissue viability product formularies and listings in hospitals across WM region, for use on all clinically relevant non-healing and complex wounds. 
Read more
Hide details
Nick Howard 12/02/2018 - 19:23 Detailed Submission Login or Register to post comments
0
0
Votes
-99999
Innovation 'Elevator Pitch':
Simple visual tools that enable people who cannot communicate to convey the location and nature of their pain or discomfort. They can then be given appropriate support and treatment.
Overview of Innovation:
Many people suffering pain and discomfort cannot tell anyone about their distress. They may have a permanent or temporary communication difficulty, or they cannot speak English. Because of this, their pain and discomfort may be ignored.
 
Show Me Where is suite of simple visual tools that enable adults and children to convey the location and nature of their pain or discomfort. They can then be given appropriate support and treatment.
 
Show Me Where was created by Irene Hammond, a school nurse from the Hollies Special School, Cardiff for children with autism and speech disabilities. These children were unable to communicate pain and were impossible to examine because of anxiety or sensory issues. 
 
Since being introduced Show Me Where has been recognised as a valuable resource for a much wider range of people in a variety of settings including clinical, education and domestic.
 
Show Me Where is available in printed and digital app versions (via Apple and Google Play App Stores) for both children and adults. The apps also offer a range of languages to facilitate communication with non-English speakers. 
  • Arabic
  • Bengali
  • Polish
  • Somali
  • Urdu
  • Welsh
Show Me Where can be used with a wide range of people and in any setting:
  • Stroke   
  • Autism (ASD)
  • Dementia  
  • Disabilities e.g. CP, MS
  • Deafness and hearing problems
  • Intubated or tracheostomy
  • Trauma or anxiety
  • Non English-speakers
"We use Show Me Where as part of the Pain Assessment and Management Toolkit for Patients with Communication Difficulties in all clinical areas. We endorse its value in clinical practice." Sue Mogford, Lead Nurse, Pain Team, Cardiff and Vale UHB

The tools are very simple to use. Affected people are presented with a version of Show Me Where and asked if they are in pain. If ‘yes’ is indicated they are shown a list of body images to select from. Very quickly an accurate assessment can be made of the location and nature of pain and discomfort. Presenting the tool on a regular basis reduces stress and anxiety and ensures the early detection of pain with vulnerable people.
 
In a clinical environment it is helpful for family, friends and nursing assistants to triage individuals and therefore support a more rapid and effective examination by healthcare professionals. It also enables clinicians to inform the patient and gain consent for medical examination and interventions.

"This app is brilliant!" Sunshine Haskell BA Hons, PGCE Teacher, The Hollies Special School
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Mental Health: recovery, crisis and prevention / Long term conditions: a whole system, person-centred approach / Digital health / Innovation and adoption / Person centred care
Benefit to NHS:
Many people suffering pain and discomfort are unable to tell anyone about their distress. They may have a permanent or temporary communication difficulty, or they cannot speak English. Because of this their pain and discomfort may be ignored. Show Me Where makes diagnosis and treatment more effective and efficient for health and social care professionals. It aslo improves the quality of life for individuals living with the pain and discomfort. Accessibility and parity are both improved.
Initial Review Rating
3.00 (2 ratings)
Benefit to WM population:
Many people suffering pain and discomfort are unable to tell anyone about their distress. They may have a permanent or temporary communication difficulty, or they cannot speak English. Because of this their pain and discomfort may be ignored. Show Me Where not only improves the detection, treatment and management of pain it makes diagnosis and treatment more effective and efficient.
Current and planned activity: 
Show Me Where has been available for some time via Cardiff and Vale University Health Board. They have entered a partnership with Focus Games Ltd to make the tools more widely available by promoting the tools more effectively. Show Me Where is officially endorsed by the following organisations
  • University Hospital of Wales (C&VUHB)
  • Llandough Hospital (C&VUHB)
  • St David's Children's Centre (C&VUHB)
  • Ty Hafan, Children's Hospice
  • Special Needs Schools in Wales
  • Welsh Ambulance Service Trust (WAST)
What is the intellectual property status of your innovation?:
IP is owned by Cardiff and Vale University Health Board
Return on Investment (£ Value): 
medium
Return on Investment (Timescale): 
0-6 mon
Ease of scalability: 
Simple
Regional Scalability:
Being widely used in hospitals and special schools in Wales.
Measures:
Improve the recognition of pain and its management among people with communication difficultis. Especially vulnerable groups.
Adoption target:
Ideally every organisation or individual that deals with people who have communication difficulties would use Show Me Where. There is no minimum viability level.
Read more
Hide details
Andy Yeoman 29/01/2018 - 09:52 Detailed Submission Login or Register to post comments
0
0
Votes
-99999
Innovation 'Elevator Pitch':
A secure training platform using high quality video content and cutting edge learning technology. We produce high-quality courses, or update or convert your existing training material accessible via smartphone, tablet or computer – anytime/anywhere
Overview of Innovation:
The medics.academy platform has been designed with security to protect against inappropriate access and copyright infringement with an option to request users to pay per view.
medics.academy combines engaging content, low cost access and accessibility. Healthcare professionals from across the UK and internationally can benefit from consistent, sustainable educational programmes that will have a significant effect on performance and patient safety.
Medics Academy (MA) - Delivery Platform - Flow diagram
medics.academy (MA) - Delivery Platform

The platform incorporates unique technology to allow high quality video content to be viewed anywhere across the world without loss of quality. This allows educators, subject matter experts or partner organisations to securely distribute high quality, high value courses that may be of a sensitive, private medical nature. Programmes for or that target their audience whilst protecting their access to them and ensuring their ownership, IP and if required to generate direct income from their content.
 
Delivery facilities:
  • High quality education online on any digital device
  • Security and IP protection of authored content
  • Global access via a specifically designed IT platform
  • Scalability and sustainability via a revenue sharing business model
  • Tracking of users and access / usage
 
MA Content Production
The company mission is to empower health professionals through knowledge so they can provide better care. The company has already developed and delivered a range of courses

Content creation opportunities:
  • Content generation/production services and expertise
    • New Training Material creation
    • Conversion of existing material
    • Adapting original material for delivery via the MA Platform
  • Visuals graphics & animation facilities to illustrate points/information
  • Option to add additional products and services, e.g. link to classroom based training
  • Quality assured and endorsed content from experts combined with other content e.g. filmed demonstrations of skills

Company Background
The founders of the company, two medics, became increasingly frustrated by the poor design, use and engagement with e-learning and believe the use of these expert driven courses can be a part of a new blended learning solution to medical education.  From their frustration and experiences, they built a team based in the UK and the US, that have developed this platform. Medical educators can focus on building amazing content, supported by a team of artists, filmmakers, engineers and medical content specialists.

 
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Education, training and future workforce / Wealth creation / Digital health / Innovation and adoption
Benefit to NHS:
Freedom of Access
Opportunity to train staff remotely at any time or place and at their own pace, the ability to deliver training content pre or post a course to either prepare or reinforce the material being delivered either as well or instead of a physically attending formal course. This secure training platform facilitates the trainer/education unit with a range of options to deliver their material to their staff and students.
 
This range of options can then be selected to best suit the ability to reach and gain access to the trainees e.g. it can facilitate them not travelling or leaving their place of work. It can be used to assist students with revision or reinforcement of a recently delivered course possibly before and exam or test.
 
This flexibility can work for the participant as well as the deliverer of content all leading to a better trained and confident workforce. Hence facilitating performance improvement and make training significantly more cost effective and efficient.
 
Usage Tracking
Material accessed can be logged along with information on viewer and duration. This is part of our security and revenue system when required and when this may be appropriate. This also gives content producers a clear idea into their most used and valuable training assets.  
 
Confidentiality & Control
Access to material can be controlled you may wish to do this to ensure that content that may be clinically sensitive (e.g. of distressing or of a possible sexual nature) or that may be commercial sensitive is not accessible by those without permission. 
 
Revenue Generation
Courses that are delivered on the platform can be via a pay per view option. This is a revenue sharing model between Vopulus and the content provider, so significant income generation can be earned by the training provider from offering their material to a global audience. We take away all the strain and complexities of an organisation creating a charging system and the processes to providing a secure and trusted credit cards charging system.
 
The Key Benefit
All you need to worry about is the material you wish to teach – we can produce that material with you and then deliver it safely to your intended or your selected audience.
 
We look forward to your call or your response below.
Initial Review Rating
3.40 (1 ratings)
Benefit to WM population:
Key Benefits
  • Simple Video Delivery Training Platform designed for Medical Content  Removes concerns over access and can form part of a library of material for a Trust or for West Midlands NHS & Community Clinical staff
     
  • Options to generate revenue from your content
    Generate money from external organisations or clinicians from your training material
     
  • Confidential and professional Training Material production or conversion
    Take the worry away from delivering, recording and illustrating your training material we will do that and if you’re not confident or comfortable being videoed we can arrange for an expert presenter to deliver your lessons
 
Enhanced Staff - Leading to better informed and trained healthcare professionals which ensures confidence that leads to improved patient safety and outcomes.
 
Training / Testing Freedom - Ability to offer courses to hard to reach clinical and medical staff due to their location (e.g. Community based) or their availability (shortages but imperative that they are brought up to date on a process or procedure). The platform allows 24/7 access to material and through the tracking a degree of confidence can be had by the trainers / management that the viewer has seen and understood the material delivered. The level of understanding can be confirmed via an online test or other assessment methods.
 
Potential Patient Use - This platform also has potential to be used for patient education programmes providing a significant increase in patient empowerment, self care and wellness.

Payment Security
The platform has a fully integrated payment system built on the industry leader Stripe. We also use a cutting edge ledger and tracking function that allows fully transparent tracking of payments for clients. Thus due incorporated Stripe system, partners/clients can be fully confident in a global payments and payment tracking system that utilises the latest technology and security standards.
Current and planned activity: 
Current Activity
  • We have a regional project underway with the West Midlands AHSN to produce training material for LTC.
  • We are having a number of discussions and negations on material related to maternity with Trusts across the UK.
  • Although we seeking to engage with more content providers and potential purchasers of group courses.
Thus we would like to discuss:
  • Procurement / Adoption of:  
    • More medical training Video productions or for more Trusts and other clinical training organisations/units to our Medical Academy Platform to deliver you material   
    • Usage of our secure and / or revenue generating video content Delivery Platform space. 
What is the intellectual property status of your innovation?:
Platform has IP associated with its design and security to protect content from plagarism.
The course content IP remains with the author apart from our newly produced graphics.
 
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
6-12 mon
Ease of scalability: 
Simple
Read more
Hide details
Johann Malawana 27/11/2017 - 15:55 Publish Login or Register to post comments
0
0
Votes
-99999
Innovation 'Elevator Pitch':
Our award winning, low cost, high impact Patient Care Packs have been developed in collaboration with over 50 NHS Trusts to address the most common needs of patients and free up front-line staff time to spend on nursing and compassionate care.
Overview of Innovation:
Patients are often admitted to hospital at short notice. This means that some come ill equipped for their stay without event basic hygiene essentials, at what is often a confusing and difficult time.
 
Evidence indicates that nurses spend more than 5 minutes per patient obtaining essential items, or people survive without, having a negative impact on their well-being and impeding nursing ability.
 
Patient Care Packs (PCP’s) include essential items (such as toothbrush, toothpaste, grip socks, ear plugs and eye mask) everything a patient needs for their own personal hygiene, protecting their dignity and enhancing the feeling of comfort.


 
Our in-house assembly offers the flexibility to tailor packs to your specific requirements and include maps, questionnaires and information about staff and facilities, which will free up staff time to spend on nursing and compassionate care.
 
University of Leicester research proves that patient care packs save nurses more than 40 minutes per shift (1:8 patient ratio) enabling more effective nursing and saving the cash strapped NHS £1,705 per band 4 nurse. Read a two page summary of the research study or download the full report here.
 
Key findings from the research study conducted by the University of Leicester include:
 
94% of patients felt that PCP’s ensured they felt cared for during their hospital stay.
 
84% of nursing staff felt that PCP’s saved them more than 5 minutes per patient, releasing at least 40 minutes per shift, improving job satisfaction for 9 out of 10 nurses.
 
93% of nurses felt that PCP’s promoted positive interactions with patients.
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Innovation and adoption / Person centred care
Benefit to NHS:
The HSCIC Indicator Portal Website show emergency hospital admissions (all conditions – data for 2014/15) in England as 5,131,589. Source: https://indicators.hscic.gov.uk/webview/
 
Hospitals have also experienced increases in the number of emergency admissions of older patients, by 18% between 2010-11 & 2014-15. Source: http://bit.ly/2tuy9we
 
The use of Patient Care Packs (PCP’s) provides tangible benefits for NHS Trusts through cost savings in procurement compared to competitor products, releasing nursing staff time and reduced demand on storage space.
 
PCP’s are essential toiletries available in one pre-packaged, easy-to-store, easy-grab pack. Receiving a pack improves the admission and care experience for even the most isolated and vulnerable patients.
 
PCP’s were piloted back in 2007 at the request of Leicester Hospital’s Chaplaincy, who were concerned that patients were being admitted with no basic care items and didn’t have family or friends nearby who could bring them essential items in an emergency situation – people like the elderly or homeless.  Staff may have had a few supplies, but these always ran out very quickly and then considerable nursing time was being expended in trying to obtain essential items for patients. A 3 year investment from the Department of Health in 2012 launched Personal Care Packs as a national social enterprise scheme.
 
PCP’s are viewed positively by nursing staff due to their role in conveniently and efficiently enhancing the quality of care to patients.
 
Patients also view PCP’s positively, perceiving that they improve their comfort, dignity and promote a feeling that they are being cared for.

Initial Review Rating
3.93 (3 ratings)
Benefit to WM population:
The HSCIC Indicator Portal Website show emergency hospital admissions (all conditions – data for 2014/15) in the West Midlands as 590,475. Source: https://indicators.hscic.gov.uk/webview/
 
The use of Patient Care Packs (PCP’s) provides tangible benefits for NHS Trusts through cost savings in procurement compared to competitor products, releasing nursing staff time and reduced demand on storage space.
 
PCP’s are sold to NHS Trusts through a social enterprise with the profits used to support the charity Giving World. These packs are distributed by nursing staff to the patients at the point of admission.
 
The attached research study conducted by the University of Leicester reported Nursing staff that use PCP’s found them beneficial in discharging their duties, enhancing the care they provide as well as leading to an increase in their job satisfaction through better patient-nursing staff relations. The use of PCP’s enables nurses to save time in performing their duties, relieving them of an administrative and logistical burden.
 
The report indicates that this time saving can be used to off-set the overall cost of the pack. The research has also provided an evaluation of the financial value of PCP’s when compared to alternative care packs. The compact nature of PCP’s also provides additional benefits in the space required to store the items.

The packs are proven to save 40 minutes per shift (assuming 8 patients cared for per shift), equating to between £8.58-£14.77 for band 4-7 staff.

Cost of 8 standard packs per shift (1 per patient) is £7.60, resulting in a saving of between £0.98-£7.17

Current and planned activity: 
We are the supplier of choice to over 50 Hospitals across the UK for customised patient care packs, including Guy’s & St Thomas’ Hospital’s Award-Winning Patient Pack. 100% of profits go to helping people living in poverty right here in the UK.
 
We would like WMAHSN to help to identify opportunities to offer Patient Care Packs to NHS Trusts in the region, enhancing the care they provide to patients by protecting their dignity and providing a feeling of comfort, as well as helping to increase the job satisfaction of nursing staff through better patient-nursing relations.
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
0-6 mon
Ease of scalability: 
Simple
Read more
Hide details
Sujata Sabharwal 06/11/2017 - 11:35 Publish Login or Register to post comments
5
1
Votes
-99999
Innovation 'Elevator Pitch':
The Hydrant is a novel and effective solution of proviiding fluids to those patients with poor mobility or requiring flat-bed rest. it consists of a bottle and drinking tube that can be postioned to allow the patient to independently consume fluids.
Overview of Innovation:
 Within the NHS dehydration remains a significant problem with recent reports suggesting it may affect as many as one in seven hospital patients and cost the NHS £1 billion a year. The majority of hydration in secondary care, is reliant on patients’ independent consumption of fluids.One way to improve hydration amongst these groups of patients is to increase accessibility of fluids using drinking aids. These aids encompass a broad range of products from insulated mugs that maintain drinks at the appropriate temperature to more complex devices designed for patients who find it difficult to drink from standard vessels. it consists of a bottle with an adjustable, self-supporting drinking tube with a bite valve that allows patients to draw fluid from the device. The device has won design awards and offers a sensible solution to providing fluids for those patients with poor mobility or physical capacity, or otherwise confined to flat-bed rest. The bottle has been trialled on the Neurosurgery ward at UHB and was greeted favourably by staff and those patients offered it. 
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Wealth creation / Innovation and adoption / Person centred care
Benefit to NHS:
Within the NHS dehydration remains a significant problem with recent reports suggesting it may affect as many as one in seven hospital patients and cost the NHS £1 billion a year (Good, Richard 2014) with elderly patients particularly susceptible due to their diminished thirst sensation and changes in kidney function (Hooper 2014).  The majority of hydration in secondary care is reliant on patients’ independent consumption of fluids.  The act of drinking appears a straightforward response to a physiological need yet it is in fact a complex behaviour determined by a variety of factors and their interactions (Koster 2009) including physical, psychological, and environmental influences (Kenney 2001). In the ward environment patients rely on the support of health care providers and yet staff frequently report a number of barriers to performing hydration care with insufficient time as a key barrier amongst them (Simmons 2001; Mentes, chang 2006). This can leave patients with limited movement, cognitive ability or higher clinical dependency particularly vulnerable to dehydration. One way to reduce this risk is to increase accessibility of fluids using drinking aids such as the Hydrant. 
Initial Review Rating
4.00 (2 ratings)
Benefit to WM population:
As above
Current and planned activity: 
The primary issue with its upatke within UHBFT was the availability of the device. Staff on wards where patients would benefit from its use were unable to procure the device.
We propose that WMAHSN facilitate a series of meetings with key staff involved in procurement at the hospital to improve the supply and availability of the bottle.
Once the bottle is more freely available we propose to raise awareness of its availability with staff on the relevant wards.
 
What is the intellectual property status of your innovation?:
Licensed product of Hydrate for Health Ltd,
http://www.hydrateforhealth.co.uk/our-products/the-hydrant/
 
Return on Investment (£ Value): 
N/A
Return on Investment (Timescale): 
N/A
Ease of scalability: 
Simple
Read more
Hide details
Ian Litchfield 03/11/2017 - 13:18 Publish Login or Register to post comments
0
0
Votes
-99999
Innovation 'Elevator Pitch':
Cladribine is a new oral therapy for the treatment of highly active Multiple Sclerosis (MS). It is effective in reducing relapses and can substantially reduce the administration and monitoring burden associated with other therapies currently in use.
Overview of Innovation:
The MS Society estimates that there are approximately 107,000 people with MS in the UK, and that each year 5,000 people are newly diagnosed with the condition. This means around one in every 600 people in the UK has MS. MS is between two to three times more common in women than men.
 
Multiple sclerosis is a chronic and debilitating autoimmune disorder of the central nervous system.  In Multiple Sclerosis, the body’s own immune cells mistakenly attack the myelin that surrounds nerve fibres, leading to nerve damage.
 
Cladribine is a small oral molecule, developed by Merck, that selectively reduces the number and activity of these immune cells (B and T lymphocytes) and modulates cytokines. There is only a transient and relatively small effect on the innate immune cells such as neutrophils.
 
Cladribine Tablets have been investigated in 4 main phase II/III studies in MS. In a Phase III study (CLARITY), 3.5mg/kg Cladribine Tablets over 2 years (n = 433) with significantly reduced annualised relapse rates (ARR) by 77.8% in patients with Relapsing Remitting Multiple Sclerosis compared with placebo (n = 437) (p<0.001).
 
A phase IIIb extension study (CLARITY EXT) confirmed that the initial 2 year treatment with 3.5 mg/kg Cladribine Tablets was effective in reducing the frequency of relapses in years 3 and 4 by 75.6%.
 
A post hoc analysis of the CLARITY data, which focused on a subgroup with High Disease Activity, provided a consistent treatment effect on relapses for Cladribine Tablets compared with placebo.
 
The safety profile of Cladribine Tablets has been thorougly investigated in the 4 main phase II/III clinical studies and an ongoing PREMIERE registry.
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Advanced diagnostics, genomics and precision medicine / Wealth creation / Innovation and adoption / Person centred care
Benefit to NHS:
  • Cladribine has the potential to deliver high efficacy without continuous suppression of the immune system;this results in a manageable safety and tolerability profile and low administration and monitoring burden.
     
  • Cladribine tablets are an oral therapy that selectively targets the immune system to produce effective disease control for up to 4 years with only 10 days of treatment per year for the first 2 years.
     
  • Cladribine tablets broaden treatment options for commissioners, clinicians and patients with highly-active MS.
     
  • Cladribine has the potential to substantially reduce the overall volume of administration and monitoring and of associated costs.
In addition, in many areas of England, MS specialist nurses (who bear much of the responsibility for administration and monitoring) are currently working at or above their patient capacity. The use of Cladribine has the potential to substantially free up this specialist nurse resource

CLADRIBINE IS THE ONLY MS THERAPY WHICH HAS RECEIVED A 'RAPID UPTAKE' DESIGNATION FROM THE ACCELERATED ACCESS COLLABORATIVE.
Initial Review Rating
4.60 (1 ratings)
Benefit to WM population:
The West Midlands Region has approximately 9,360 MS patients of which 1,363 are
estimated to be on MS treatments for highly active MS.
 
If these 1,363 patients had been treated with Cladribine as opposed to current therapies, an estimated saving of £18.1 million could be made over a 4 year period.
The above figures do not include the 20% VAT which is charged on MS therapies which are dispensed and administered in hospital Trusts (mainly infused MS therapies).

In addition,the availability of an oral alternative reduces the need for patients to attend hospital Trusts which may be located substantial distances from where the patients live.
Current and planned activity: 
Current activity
An agreement has been made with NHS England which provides an up front discount and also a rebate if the product is discontinued and replaced by another MS therapy during the expected 4 yr treatment window. 
NICE approval occured on 6th Dec.2017( TA 493 ).
Planned activity
MS treatments are traditionally prescribed by MS specialists based in hospital Trusts. However, the bulk of the costs of administration and monitoring are borne by CCGs.
Increases in the volumes of monitoring of specialised medicines are also creating service and governance challenges in some localities.
 
There is therefore a need to move from taking a purely secondary care to a cross-sector perspective when considering which treatments are most clinically and economically appropriate.
 
The support of West Midlands AHSN would therefore be very much welcomed in facilitating discussions between the relevant service stakeholders and to ensure a cross-sector perspective.
What is the intellectual property status of your innovation?:
The product license holder in the UK is Merck Serono Ltd
Return on Investment (£ Value): 
Very high
Return on Investment (Timescale): 
3 years +
Ease of scalability: 
Simple
Read more
Hide details
Richard Lomas 27/06/2017 - 13:14 Publish 1 comment
0
0
Votes
-99999
Innovation 'Elevator Pitch':
A web based solution addressing some major pain points for Health and Social Care - Cost Savings, visibility of available beds, A&E congestion, Delayed transfer of Care (DToC). We also provide a single Command & Control Centre for Major Incidents
Overview of Innovation:
Our  web solution offers:
Real-time visibility of available beds: For all care Professionals across multiple care domains and a wide geographical area, including Hospitals, Trusts, Boroughs and event Social Care block booked beds. A search for any bed type across any care domain in a city, region or entire country yields results in a matter of seconds.

A&E: Visibility of volumes waiting in A&E, their individual waiting times/times to breach and the ability to Triage score each and every one of them. From this, A&E departments can at least make informed decisions and prioritise well in advance of any bed availability issues.

Early warning system: Thresholds may be set by hospital management, particularly around A&E, Emergency and Acute bed types. These thresholds are then monitored in real-time by our solution, without any additional user intervention. An algorithm we created takes these thresholds and compares them with existing bed levels in order to provide an overall, colour coded hospital status indicator in line with the recent OPEL standard (NHS England 2016). This status indicator also provides colour coded status for each of these key bed types. Simply put it is an early warning system available for every care professional in the hospital setting so that they can all see where pressures are quietly building and take a more proactive approach to hospital status before a crisis occurs.

Outside the hospital: To assist those in search of available beds, such as bed managers from other hospitals, GP’s and other care professionals, our solution also provides a high-level view of a hospital’s current status to this wider audience. This approach makes clear whether a hospital or hospitals are currently experiencing difficulties and thus reduce the chance of blindly picking up the phone or making e-mail enquiries on available beds to a hospital that is already struggling.

Dynamic sitrep: Removes the need for lengthy update meetings. Sitrep++ provides real-time admit/discharge information instantly.

DToC: Identifies DToC the moment they occur and offers a collaborative approach for both Health and Social Care to manage and reduce DToC via a single interface. We provide full cost and delay duration/impact stats in realtime too, thus removing the overhead from the individual.

Major Incidents: Our Command & Control Centre feature allows co-ordination of multiple A&E's across an entire city via a single interface.

Our feature rich solution does much more.
 
Stage of Development:
Evaluation stage - Representative model or prototype system developed and can be effectively evaluated
WMAHSN priorities and themes addressed: 
Digital health / Innovation and adoption
Benefit to NHS:
A&E congestion and waiting times: Just a 10% reduction in A&E breaches means that around 33,000 patients, per year, would wait less time to receive the appropriate level of care.

Delayed Discharge: A mere 5% reduction in DToC 'Bed Blocking' means a £45m per year saving for NHS alone. That's a reduction of 78,000 delay days; meaning that 6000 more people could receive treatment with the same bed count and less effort. The reduction in managing and reporting overheads for both Health and Social Care are also significant.

Efficiency: Precious time spent on day to day administration for both Heath and Social Care is enormous. Entry of the same information over and over again, manually counting available beds in times of crisis, bed managers glued to the telephone dealing with inquiries and multiple sitrep meetings, each slowly grinding care professionals into the ground. In these areas NHS and Social Care could realise a 90% reduction in effort/time. In a population of 200 GP's and 200 Bed Managers that equates to circa £8m year on year. GP's could locate an approapraite 'available' bed for their patient in seconds without a single e-mail or phone call. Social Care would be able to locate and Block booked bed or Care home bed anywhere in the country in seconds

Command & Control Centre:  In the event of a Major Incident - A single Command & Control enables NHS to manage/co-ordinate multiple hopsital locations from a single interface and direct Ambulance Servcies more efficiently.
Initial Review Rating
4.20 (1 ratings)
Benefit to WM population:
A&E congestion and waiting times: Just a 10% reduction in A&E breaches means that around 33,000 patients, per year, would wait less time to receive the appropriate level of care.

Delayed Discharge: A mere 5% reduction means a £45m per year saving for NHS. That's a reduction of 78,000 delay days; meaning that 6000 more people could receive treatment with the same bed count and less effort.
 
Current and planned activity: 
We are trying to gain traction with both NHS and Social Care which is notoriously difficult. Our planned activity is to engage with a number of key hospitals and boroughs to showcse our solution. This is the area where we require support in securing the inital contacts and interst in NHS/Social Care.
What is the intellectual property status of your innovation?:
We have the intellectual property of our solution already secured.
Return on Investment (£ Value): 
N/A
Return on Investment (Timescale): 
N/A
Ease of scalability: 
Simple
Regional Scalability:
By design, a web based application is built to scale and is available via the usual suite of internet browsers.
Scaling across West Midlands: expected user footprint is circa 250 'concurrent' users
based on 19 Acute, 6 Mental Health, 1 Ambulance trust/s and 7 Social Care boroughs.
Measures:
Outcome: Greater efficiency within Hospitals:
Measure: Before and after comparison on visibility of available beds - quality and cost/time saving
Measure: Impact upon Patient flow
Measure: Impact upon A&E volumes, breaches and management effort, for time/cost saving.
Measure: Before and after DToC volumes, management and reporting effort on time/cost saving
Measure: Cost/time saving v cost of solution
Measure: feedback on impact of application wrt visiblity and ease of use.
Measure: Patient feedback

Outcome: Greater efficiency for Social Care
Measure: Before and after levels of visibility and availability of block-booked or normal care home beds
Measure: Before and after DToC volumes, management and reporting effort
Measure: Care Professional feedback

Outcome: Patient satisfaction
Measure: A&E waiting times and volumes
Adoption target:
Adoption Target: All Acute, Mental Health and Ambulance Trusts in the region.
Minimum viability: 4 Major hospitals in the region along with corresponding Social Care boroughs.
Read more
Hide details
Paul Rylance 16/06/2017 - 20:04 Detailed Submission Login or Register to post comments
0
0
Votes
-99999
Innovation 'Elevator Pitch':
Children are at risk of serious harm or even death because adults are mixing alcohol consumption with caring and parental responsibilitie. This campaign poses the question - "when parents drink, who's in charge?'
Overview of Innovation:
Parents from all backgrounds are putting their children at risk when they drink alcohol at home.

The 'Who's In Charge?' campaign from Birmingham Community Healthcare NHS Trust depicts real life child harm scenarios and asks – ‘when you drink, who’s in charge?’

The campaign was conceived in response to concerns that growing numbers of babies and children are at risk of serious harm because of the way their parents consume alcohol at home.

Safeguarding professionals warn that children are being placed in danger and even losing their lives because adults who in many cases do not consider themselves excessive drinkers are not exercising normal levels of care and attention while drinking or recovering from the after-effects of over-indulgence in alcohol.

And they warn of a ‘double jeopardy’ effect - that drinking too much alcohol can not only reduce a parent’s capacity to appropriately respond to children’s needs, but also make the drunken adult an active danger to the child.

One of the most worrying trends identified locally and nationally is a rise in the number of baby deaths connected with sleeping on a sofa with an adult who is under the influence of alcohol, the number of children left to care for their younger siblings and the impact of the example of parents’ drinking patterns on young people.

The number of victims of Sudden Infant Death Syndrome who were sleeping with a parent on a sofa has risen.

The campaign urges parents, and others with responsibility for children, to be aware of a range of potentially dangerous consequences if no adult remains sufficiently sober and aware of children’s needs or whereabouts.


In one year in Birmingham alone: 
  • 82% of babies who died from Sudden Infant Death Syndrome were sleeping with a parent at the time
  • 56% of these deaths were on a sofa; 44% in the parental bed.
  • 78% of the fatalities were associated with parental alcohol use at the time
  • while 44% involved parental drug use.
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Mental Health: recovery, crisis and prevention / Wellness and prevention of illness / Education, training and future workforce / Person centred care
Benefit to NHS:
  • supportive of statutory safeguarding responsibilities through reduced risk of harm to children and young people
  • supportive of adult clinical services due to reduced risk of harm to adults through excessive alcohol consumption.
  • community cohesion
  • marketing and education resources for professionals eg. health visitors, school nurses.
Initial Review Rating
3.60 (2 ratings)
Benefit to WM population:
  • reduced risk of harm to children and young
  • reduced risk of harm to adults through excessive alcohol consumption.
  • community cohesion
Current and planned activity: 
A set of photographs has been commissioned depicting hard-hitting photographic case study scenarios based on real life evidence from serious case reviews and other reported incidents.

AVAILABLE TO OTHER TRUSTS FREE OF CHARGE - If you wish to use these in your organisation, please contact David Disley-Jones or MidTECH Innovations (www.midtech.org.uk).

A simple logo was designed and has been trade-mark protected with the IPO.
A set of posters has been produced which have been displayed in a variety of locations.
A set of aide memoire cards has been produced for use by professionals such as health visitors and school nurses to generate discussion and raise awareness.
Who's In Charge? has been licensed to British Armed Forces in Germany for use on military bases, in acknowledgement of the issue of alcoholic consumption among military families.

 
What is the intellectual property status of your innovation?:
The logo and the use of the phrase 'Who's in Charge?' (in certain contexts) has been trade-marked with the IPO.
The photographs are copyright BCHC/Roy Peters Photography.
Return on Investment (£ Value): 
low
Return on Investment (Timescale): 
3 years +
Ease of scalability: 
Simple
Co-Authors:
Read more
Hide details
David Disley-Jones 30/05/2017 - 17:05 Publish Login or Register to post comments
0
0
Votes
-99999
Innovation 'Elevator Pitch':
Coronary Artery Disease (CAD) is the leading cause of death world-wide. HeartFlow’s non-invasive technology, FFRct, has been found to accurately diagnose patients with suspected CAD, avoid unnecessary invasive procedures, and reduce healthcare costs
Overview of Innovation:
The diagnosis and care of patients with suspected coronary artery disease is significantly improved by the use of HeartFlow's FFRct analysis. Our process starts with data from a standard Coronary Computed Tomography Angiography (CCTA). High-quality (64 slice or greater) CT scanner images are sent to HeartFlow.

HeartFlow then creates a personalized, 3D model of each patient’s arteries. Where computational fluid dynamics are used to evaluate blood flow and assess the impact of blockages in the arteries. With this actionable information, clinicians can determine the right course of action for each patient.

While FFRct is still in an early  stage of adoption, there are now over 150 publications on the technology. Clinical trials have validated both the diagnostic accuracy and clinical utility. Most recently NICE issued guidance on HeartFlow FFRct, stating "The technology is non-invasive and safe, and has a high level for diagnostic accuracy... may avoid the need for invasive coronary angiography... Based on current evidence using HeartFlow can lead to cost savings of £214 per patient."

CT data is securely (Anonymised CCTA data) and seamlessly sent via our “HeartFlow Connect” once installation is approved by the hospital trust. HeartFlow ensures that the scans and FFRct results and analysis models are acceptable to a sites radiologists / radiographers.
 
Whilst this is an emerging diagnostic its well positioned to become an integral part of standard patient care for those who are at risk of CAD. As this is a new technique HeartFlow provides training to radiologists, radiographers, cardiologists and support staff. We work closely with each site to provide support and training to help evaluate the technology and as they begin to incorporate FFRct into their clinical practice. [A high level overview of HeartFlow’s training support can be found in the Adoption guide published by NICE. (see attached)]
 
HeartFlow FFRct users are invited to educational seminars and we are working on establishing a UK users group to help sharing best practice around FFRct’s use.
 
HeartFlow has received CE mark approval for use in UK/Europe.  CCTA image specifications for HeartFlow FFRct analysis; HeartFlow’s CCTA quality requirements are consistent with those of the Royal College of Radiology (RCR), British Society of Cardiovascular Imaging and the Society of Cardiovascular Computed Tomography (SCCT) performance of CCTA guidance document.
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Advanced diagnostics, genomics and precision medicine / Wellness and prevention of illness / Wealth creation / Clinical trials and evidence / Digital health / Innovation and adoption
Benefit to NHS:
The use of HeartFlow FFRct can improve patient care, efficiency, and lower medical costs:

Patient Care
  • HeartFlow FFRct provides a physician with both functional and anatomical data, improving diagnostic accuracy, thus reducing invasive procedures and associated complications
  • Improved diagnostic accuracy improves patient care and quality of life
  • Studies suggest that incorporating FFRct lowers patient radiation levels due to decreased angiography
Efficiency
  • Studies indicate that the application of FFRct may result in a reduction of unnecessary angiographies, improved cath lab efficiency, and reduced waiting lists
  • By providing both functional and anatomic data, physicians may be able to reduce the need for and waiting times associated with other diagnostic imaging tests
Cost of Care
  • As demonstrated in the NICE guidance, the use of HeartFlow FFRct can potentially reduce the cost of care. NICE estimates an average savings of £214 per patient. This saving is based on not conducting inappropriate invasive diagnostics.
  • A Japanese study has indicated that the use of the CCTA-FFRct strategy to select patients for Percutaneous Coronary Intervention (PCI) would result in 32 % lower costs and 19 % fewer cardiac events in 1 year compared to the most commonly used CAG-visual strategies. 
 
“The HeartFlow FFRct Analysis provides a definitive understanding of both anatomical and functional findings, without any additional testing or risk for patients. Application of the HeartFlow FFRct Analysis is likely to transform the quality of care we can provide for patients, ensuring the most accurate diagnosis and the best treatment plan, as well reducing the need for invasive coronary angiography – a procedure not without its risks.”
  -  Dr. Joseph Mills, Liverpoool Heart and Chest Hospital
Initial Review Rating
4.60 (1 ratings)
Benefit to WM population:
As stated in the NICE guidance, the adoption of HeartFlow FFRct in the West Midlands region could improve patient care and outcomes while generating significant savings for the region.
 
We are looking for additional adoption sites and would be interested in hearing from West Midlands Trusts that would like to take the lead in establishing our UK user group.  
Current and planned activity: 
HeartFlow is in early conversations with NHS Trusts and commissioners. A handful of early adopting NHS medical centres have begun to provide HeartFlow FFRct for their patients. HeartFlow is engaging with interested physicians at centres with high quality CT capabilities.

UK Sites where Heartflow FFRct is being used:
  • St. Bartholomew’s Hospital (London)
  • Liverpool Heart and Chest
  • Russell Hall Hospital (Dudley, West Midlands)
  • Freeman Hospital (Newcastle)
HeartFlow is in discussion with other UK site about adoption of FFRct.

Planned / required activity
  • We are looking for additional adoption sites and would be interested in hearing from Trusts that would like to take the lead in establishing our UK user group 
  • Whilst we have undertaken worldwide studies we are always interested in ongoing evaluation / validation and collaborative developments technically and with clinical pathway integration.
  • In the future we plan on conducting clinical trials based & focused on specifically the UK population.
What is the intellectual property status of your innovation?:
HeartFlow has established significant intellectual property and has been issued several patents.
HeartFlow received CE IIA mark approval for use in UK/Europe in July 2011. The technology is also ISO 13485 certified.  

Return on Investment
Savings have been demonstrated in clinical trials (PLATFORM), third party health economic modelling (NICE guidance, Int’l Journal of Cariology 183 (2015) 173-7), and real world experience at early adopting centres.
 
NICE recommendations for Heartflow FFRct (February 2017) state:  “Using HeartFlow FFRct may lead to cost savings of £214 per patient. By adopting this technology the NHS in England may save a minimum of £9.1 million (annually) by 2022 by avoiding invasive investigation and treatment.  
Return on Investment (£ Value): 
Very high
Return on Investment (Timescale): 
6-12 mon
Ease of scalability: 
2
Regional Scalability:
Liverpool Heart and Chest has performed more HeartFlow analyses than any other site. They have demonstrated clinical and economic benefits to incorporating HeartFlow FFRct into their practice. The uptake is due in part to to the strong support from their regional CCG.
Measures:
HeartFlow is seeking to achieve the following outcomes:
 - Improved patient care: Reduction in unnecessary invasive angiographies and eventually a reduction in waiting times for those patients that need angiographies
 - Reduction in Healthcare Costs: NICE estimates cost savings of 214 GBP per patient. We are working with existing sites to demonstrate real world outcomes.
 - Quality of Life: HeartFlow's clinical utility trial, PLATFORM, demonstrated an improvement in quality of life when FFRct was incorporated into patient care pathways. It is likely that this is in part due to the avoidance of unnecessary interventions. To date we have not seen any adverse events from avoiding invasive procedures.   
Adoption target:
NICE estimates cost savings of 9.1M GBP annually within five years. To reach this objective approximately 35,000 patients would need to have access to a HeartFlow FFRct analysis. 
Read more
Hide details
Ben Forrest 12/05/2017 - 18:12 Detailed Submission 3 comments
5.7
3
Votes
-99999
Innovation 'Elevator Pitch':
Airglove is a patient warming system that gently heats the arm, raising fragile or hidden veins, making them easier and less painful to access.
 
“Up to 35% of patients require heated cannulisation due to fragile or hidden veins”
 
Overview of Innovation:
Airglove is a unique warming system developed to enable access to the veins in a patients arm for the delivery of intravenous drugs. It gently heats the patients arm up as it forces warm air through a single use double walled polythene glove.


www.greencrossmedico.com/products/airglove

Patient Solution
Airglove warming system works in just 3 minutes gently heating the patients arm to the selected temperature. Its so easy to use the nurse/practitioner simply selects the chosen temperature setting according to the patients skin type, places the patents arm in the double walled polythene glove and selects start. The patient will feel the warm air fill the glove up and vent away through a single slit perforation and after 3 minutes the machine will automatically stop with an alert sound.

Patient Clinical Considerations
With extended courses of treatment such as chemotherapy repeated cannulation is often required. Airglove can benefit fragile or hidden veins by warming the local area which gently raises the veins allowing for the insertion of the cannula. This reduces the time taken, costs and the number of attempts required which is more comfortable for both the patient and nurse/practitioner.

Patient Comfort
In addition to the benefits of easier cannulisation Airglove can help to make the patient more comfortable and relaxed with its gentle warming system with the confidence that the nurse practitioner will be able to access their veins.

Temperature Settings
The temperature can be selected to suit each skin type sensitive 31.5C, normal 35.5C or slightly heavier 38.5C with the Airglove automatically re-setting itself to normal skin type (setting 2: 35.5C) after each use. After 3 minutes the Airglove unit automatically switches off with an alert sound.

Patient Safety
No more improvisation with warm water, heat packs or even heated towels to try and gain access to patients veins which can be a Health & Safety issue.

Approved Medical Device
Airglove has taken 5 years of development, research, testing and trials by Green Cross Medico in conjunction with NHS Innovations South East and The Maidstone and Tunbridge Wells NHS Trust hospital. It was developed as there was a clearly defined and acknowledged need by medical professionals at The Maidstone and Tunbridge Wells NHS Trust hospital oncology department. Further trials will be starting shortly with Beatson West of Scotland Cancer Centre, Glasgow.
 
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Wellness and prevention of illness / Wealth creation / Clinical trials and evidence / Patient and medicines safety / Person centred care
Benefit to NHS:
Airglove was initially developed for chemotherapy patients who have hidden or fragile veins and especially in patients who are in their 5th or 6th cycle of therapy.

The use of Airglove affords easier cannulation with fewer attempts being required (sometimes up to 6 attempts by 3 different staff can be attempted to access a difficult vein). This improved ease of access not only makes the patient’s experience far less traumatic, but ensures a better clinical outcome and saving valuable nursing/practitioner time and consumables.

Data regarding patient experience and resource savings. Patient evaluation trials at Maidstone and Tunbridge Wells Hospital NHS Trust showed 87.5% success in cannulation on first attempt with the most difficult to cannulate patients. With cannulation success, the potential cost savings on consumables are up to £50k per oncology unit, plus the nursing/practitioner’s time. Airglove is now available and is in use or on trial in over 10 hospital trusts with more waiting for demonstrations.

Improved hygiene and reduced risk of cross infection will result from the use of Airglove vs currently used methods of locally heating the arm e.g. hot towels or buckets of warm water. Only Airglove’s single use only, double walled polythene sleeve comes into direct contact with the patient’s skin. Heated air is circulated between the double wall of the sleeve and is not directly blown across the skin and so the risk of cross contamination is reduced.

Airglove can also be used for other interventions where venous access proves difficult due to fragile or difficult to find veins e.g. routine phlebotomy.

Airglove has been developed in partnership with NHS Innovations South East and The Maidstone and Tunbridge Wells NHS Trust Hospital (MTW). It has undergone testing by the Electronics and Medical Engineering (EME) trials for temperature control and stability, and on a cohort of healthy volunteers. The Maidstone & Tunbridge Wells NHS Trust has completed the patient evaluation trials with the oncology department. They achieved 87.5% 1st time success with their hardest to cannulate patients (MTW report available).






 
Initial Review Rating
3.00 (1 ratings)
Benefit to WM population:
The West Midlands patients and healthcare system would equally share the benefits described above for the NHS in general.

There are 13 NHS Trusts within the West Midlands having oncology departments.
 
Current and planned activity: 
Airglove is now available in the UK.

If you would like to trial Airglove for 4 weeks contact Sheena Jack 07944 519796 or email: sheena.jack@greencrossmedico.com

Airglove has been developed in partnership with NHS Innovations South East and The Maidstone and Tunbridge Wells NHS Trust Hospital (MTW). It has undergone testing by the Electronics and Medical Engineering (EME) trials for temperature control and stability, and on a cohort of healthy volunteers. The Maidstone & Tunbridge Wells NHS Trust has completed the patient evaluation trials with the oncology department. They achieved 87.5% 1st time success with their hardest to cannulate patients (MTW report available).




We are also working on a further evaluation with the Beatson West of Scotland Cancer Centre, Glasgow, along with NICE Medical Technologies Evaluation Programme.


 
What is the intellectual property status of your innovation?:
Airglove is a registered Trademark.

Airglove is Patented Internationally.
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
3 years +
Ease of scalability: 
Simple
Regional Scalability:
We have not implemented in scale in any other region yet, as the product will not be available commercially until June 2018. From this point on it will be available to purchase across the West Midlands region directly from Green Cross Medico until available through NHS supply Chain.
Measures:
The success of the innovation will be measured by the uptake of Airglove throughout all 160+ oncology units throughout the UK.

This will also be determined by the cost savings to the NHS, along with patient comfort and safety, which will be assessed from the success of the patient evaluation and clinical trials.

Adoption target:
If Airglove is adopted by the 13 NHS Trusts in the WM region into their respective 14 oncology units, supplying 3 Airglove units per oncology unit, this represents 42 Airglove units using 127,400 gloves per annum.

This could generate potential savings of £369,460 per annum to the Regional NHS.

Our trials and experience to date has demonstrated that the use of the Airglove system improves the efficiency of the nurse/practitioner, coupled to the direct consumable cost savings mentioned previously....in addition to the patient comfort benefits.

We can see from the Maidstone & Tunbridge Wells service evaluation how much of a difference it makes to the patients comfort and safety when they can be cannulated successfully on the first attempt, and to take this to the next level where all patients not just oncology can get the benefit as there are a lot of 'old and cold' as we say that are hard to cannulate and are dehydrated too.
Adoption target:
If Airglove is adopted by the 13 NHS Trusts in the WM region into their respective 14 oncology units, supplying 3 Airglove units per oncology unit, this represents 42 Airglove units using 127,400 gloves per annum. 

This could generate potential savings of £369,460 per annum to the Regional NHS.
Read more
Hide details
Sheena Jack 10/04/2017 - 15:29 Detailed Submission 1 comment
5
1
Votes
-99999
Innovation 'Elevator Pitch':
Radar supports health and social care organisations in holistically managing all aspects of their quality and compliance activity, whether intuitively building a CQC evidence portfolio or managing audit, incidents and risk.
Overview of Innovation:
Radar Healthcare system has been developed using the latest technologies and platforms to ensure a cutting edge and sustainable solution. The system adopts proven business rules in use across the health & social care sector in the UK and incorporates the Care Quality Commission (CQC) guidelines and procedures.
 
Radar Healthcare from Smartgate Solutions has been developed in partnership with knowledgeable and respected healthcare professionals. The system is scalable and configurable to organisational needs to meet both internal and regulatory requirements.

The Radar Healthcare modules help care providers meet their daily operational challenges and associated quality and compliance requirements. 
 
Radar supports organisations by: Taking the worry out of quality & compliance
  • A responsive system, allowing you to visualise and manage risk, training and regulatory compliance across the business domain.
Gain a clear line of sight into performance
  • Intuitive and dynamic dashboards providing real-time visibility of business performance at both location and organisational levels.


Automation of key procedures for operational efficiency
  • Translating business rules and SOP’s into action through our automated workflows and action tracking.
Reduce costs
  • Supporting a systems approach delivering demonstrable ROI across business resources, time and staffing.
 Radar Healthcare is currently in use across multiple service areas including Social Care, Primary Care, Specialist Clinics, Acute Care  and Patient Transport.
 
It’s primary purpose is to assist in ensuring each organisation meets relevant regulatory compliance standards and support organisations reduce duplication and effort in managing that process.
 
It will allow existing processes and procedures to be followed more efficiently and enable the introduction of new processes and procedures that are currently unfeasible with existing systems.
 
Key Facts
  • The system is made up of specific modules, each providing a range of functions that can support organisations in their daily operational activity.
  • All Modules work collaboratively and share data to avoid duplication.
  • Data can be integrated from various sources and other software system.
  • Dashboards and reports can be viewed and created by employees, by department, by directorate or as an entire organisation.
  • Each module has the ability to accommodate pre-configured workflows aligned to your existing SOPs, policies and procedures.
 www.smartgatesolutions.co.uk
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Education, training and future workforce / Wealth creation / Digital health
Benefit to NHS:
Radar Healthcare modules have been developed to help care providers meet their daily operational challenges and associated regulatory requirements. 
 
Adopting proven tool kits and processes, Radar Healthcare ensures compliance with the essential standards relating to the quality and safety of care as defined within the CQC and other regulatory bodies.
 
Cost Improvement (CIP) Opportunities
The CIP opportunities are variable and based upon the modules selected. Efficiency savings are realised through two specific means:
  1. Replacement of existing systems in use across the organisation
  2. Redeployment of posts supporting quality and compliance management and re-deploying skills to vacancies within the organisation
 
A high level simulation exercise exploring how the implementation of Radar could support the reduction of cost within an NHS Hospital in the North of England (approximately 3,500 staff serving a population of c250,000 people) identified potential savings of over £300,000 over a 3 year period.
 
Smartgate Solutions have developed a cost calculator capable of identifying cost against current systems and workforce requirements.
 
Efficiency Savings
Additional efficiency improvements can be realised through:
  • Ensuring compliance with CQUIN targets or other commissioning KPIs
  • Improved efficiency and productivity in managing quality and compliance activity
  • Smartgate can support organisations with their recruitment processes and reduce the time spent undertaking training post employment. Radar allows you to issue training and development content to employees prior to their engagement and for completion online, effectively tracking and monitoring their progress against the training content.
  • Reducing the time spend responding to requests from regulatory bodies and building evidence portfolios. Radar supports the on-going development of evidence portfolios, providing clear audit trails and concise reporting.
  • The system intuitively allows users and organisations to share information, allocate tasks and distribute vital information in real time. It provides a safe and effective way of sharing learning and information.
 Client Testimonial
“We are committed to delivering the highest levels of service and CQC compliance. Radar Healthcare has been the key factor in achieving and exceeding these goals.“
John Butterfield, CEO, ER Systems
Initial Review Rating
5.00 (1 ratings)
Benefit to WM population:
Radar supports providers and commissioners of health and care services to effectively manage and monitor their quality and compliance expectations, deliverables and regulatory requirements with greater efficiency and often with greater effectiveness.
 
Radar enables organisations to re-deploy their scarce resources to focus on the delivery of care, freeing clinical expertise from administrative activities. 
Current and planned activity: 
Current NHS Activity:
Radar is currently utilised by numerous providers of health and care services, many of which provide NHS services.
 
We are currently engaged in discussions with both CCGs and NHS Foundation Trusts.
 
At present we are exploring opportunities to grow our engagement with NHS organisations and are seeking support and guidance from colleagues at WMAHSN, Medilink WM and the wider regional health and social care communities.

Planned/required activity:
  • Procurement / Adoption of: -  Growth and increased adoption of Radar across NHS provider and commissioner organisations  
  • Partnership: We are interested in exploring partnership opportunities with NHS organisations that may help to realise a financial ROI
What is the intellectual property status of your innovation?:
All product IP is wholly owned by Smartgate Solutions Ltd
Return on Investment (£ Value): 
Very high
Return on Investment (Timescale): 
0-6 mon
Ease of scalability: 
2
Read more
Hide details
Tom Lindley 30/03/2017 - 11:44 Publish Login or Register to post comments
0
0
Votes
-99999
Innovation 'Elevator Pitch':
In healthcare settings, Splunk is a powerful, easy-to-use business intelligence tool that analyses real-time data from multiple sources — enabling managers to run more efficient healthcare services.
Overview of Innovation:
Unlike other business intelligence tools, Splunk is platform-agnostic and can address ‘ad hoc’, non pre-programmed questions. Converging Data Ltd provides secure, on-premise or a hybrid cloud solution that combines and analyses structured & unstructured data from multiple sources, including but not limited to HL7 data, even collecting data directly from internal data networks.
 
This data can be interpreted without the need for predefined schemas and structures, providing real-time performance monitoring across entire care pathway.
 
Converging Date Ltd has created specific healthcare applications utilising the Splunk software platform.

Splunk makes it simple to collect, analyse and maximise the value of big data generated by security systems and business applications and improve operational performance and results.

Healthcare Intelligence
Healthcare Services & Care Pathways can be visualised and analysed using the IT Health Intelligence solution & HIX (HL7 Health Intelligence Connector).
 
Gathering data from multiple sources, in different formats and without consistent standards is what Splunk does best. HIX takes HL7 data from PAS, Pathology, Pharmacy or Electronic Health Records and provide a clear picture of how care is being delivered in real time.


HIX allows organisations to easily collect HL7 data commonly transferred between clinical and administration systems.
 
The Care Pathway Profiling tool allows data to be represented in a form that can be mapped to local physical or logical care pathways.  Alerting options ensure that the right people are notified when thresholds in service levels are reached.
 
Patient Flow
This powerful, easy-to-use business intelligence tool analyses real-time data from multiple sources, enabling managers to run more efficient healthcare services. By gathering existing structured and unstructured data from across the organisation Splunk allows healthcare providers to view the entire care pathway and direct resources to address rapidly changing conditions.
 
The Patient Flow module can easily be tuned to match local care pathways and service delivery models. Advanced analytics can be used to track organisation’s KPIs and highlight anomalies & identify root causes.

The Patient Flow module uses the Healthcare Common Information Model (HCIM) that ensures data received from multiple systems can be mapped to HL7 standards and local nomenclature. HCIM allows searching and reporting across systems which are interdependent, but not interconnected.
 
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Wealth creation / Digital health / Patient and medicines safety
Benefit to NHS:
The use of real-time data allows resources to be more efficiently deployed and problems to be more easily identified and addressed. Our ability to deploy across existing data sources means it’s fast to deploy and can demonstrate value within days.
 
We have worked with healthcare organisations to improve operational efficiency tracking patient flow, demographic breakdown of A&E arrivals, real-time location services within healthcare organisations. This allows more to be delivered with fewer resources and equipment and services to be tracked and located more quickly.
 
We have also provided detailed reporting and analysis of operating theatre utilisation and the actual costs associated with delivery of specific procedures. The real-time nature and alerting capability means that this is no longer a retrospective view, but an up to date view of what’s happening right now within a complex organisation.
 
Our Analytics Capability can also be used to address cyber security. The Splunk platform once deployed, delivers a powerful analytics driven Security Information and Event Management (SIEM) capability.
  • Splunk is installed within the NHS, and within one of the UK’s largest private hospitals.
  • Splunk is used to support NHS Digital services such as Spine and NHS Choices. 
  • Internationally we are working with Public healthcare organisations in Australia.
 NHS Choices: ‘By using Splunk Enterprise, NHS Choices has been able to improve the service it delivers to website users. The organization is now looking at new ways to deliver value from its website data, including helping the partner team track usage of content provided to over 600 syndication partners, and building product-specific dashboards for the product owners showing detailed performance and transaction status for key areas of the site’.

www.convergingdata.com
 
Initial Review Rating
4.20 (1 ratings)
Benefit to WM population:
Benefits from the deployment of this technology will be realised through better utilisation of resources and the ability to view the status of the organisation in real-time.
Current and planned activity: 
Current NHS Activity:
Rotherham NHS Trust (Pathology and Laboratory Data Services) - use Splunk to collect HL7 Data and provide visibility across Pathology and Laboratory activity.

NHS Digital: Splunk is used by NHS digital to support national IT infrastructures such as Spine and NHS Choices.

Planned/Required Activity: Planning Stage
Luton & Dunstable NHS FT  - NHS Patient Flow and Capacity Management System – to provide visibility across the patient care pathway. Splunk will be used to ‘pull’ data from clinical and administrative systems from across the Trust, including HL7 Data, creating dashboards, reports and alerts to show activity and highlight bottlenecks. Deployment initially with internal systems then rolled out to 3rd party organisations who provide care.

International:
  • Middlesex Hospital USA
  • Ongoing projects with Australian Department of Health and the Australian Digital Health Authority.
  • We are also supplying analytics capabilities into one of the UK’s largest private hospitals.
What is the intellectual property status of your innovation?:
IP protection is afforded by a mix of proprietary applications with Converging Data IP in some connectors and point applications.
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
0-6 mon
Ease of scalability: 
Simple
Read more
Hide details
Neil Murphy 29/03/2017 - 16:34 Publish Login or Register to post comments
0
0
Votes
-99999
Innovation 'Elevator Pitch':
ScanNav is a software package providing discrete, real-time support to sonographers during the FASP 20 week fetal anomaly ultrasound scan. ScanNav acts as a helpful peer review, an intelligent checklist ensuring complete, fit for purpose scans.
Overview of Innovation:
ScanNav® is a software package that provides support to sonographers during the 20 week fetal anomaly scan. It gives real time feedback to the screener on whether paused images are fit for purpose, and on whether the protocol has been followed. It is a peer review, a checklist with which the sonographer may disagree at any time.
  • Trained by human experts
  • Consistent
  • Objective
  • Always available
ScanNav:
  • Supports and assists in the supervision of newly qualified sonographers.
  • Provides oversight of locum sonographers.
  • Performs automated, prospective second trimester anomaly scan audit.
  • Provides real-time support for sonographers.
Newly qualified sonographers ideally need another sonographer in the room to assist with their scanning and with quality control, but peer review is time consuming, disruptive, subjective, and a more senior sonographer can’t be there 100% of the time.
 
ScanNav® automatically examines each image as soon as the sonographer presses pause.
It determines which (if any) FASP fetal anatomy view it represents. It then assesses fitness for purpose against the FASP criteria, reporting that opinion graphically, and giving the sonographer the option to disagree if they wish.
 
If the sonographer agrees, then no interaction is necessary.
 
If the sonographer choses to save the image, ScanNav® adds those criteria to the overall record of the view.
 
A separate interface allows managers to examine individual scans or aggregate performance against FASP criteria.  Over time, as the system observes many scans, statistics on scan completeness and quality are collated and can be presented as an audit report.
 
The sonographer always retains primacy. ScanNav® acts as a consistent colleague. ScanNav® always allows the sonographer to disagree with it.
 
www.intelligentultrasound.com
Stage of Development:
Close to market - Prototype near completion and final form may require additional validation/evaluation and all CE marking and regulatory requirements are in place
WMAHSN priorities and themes addressed: 
Wealth creation / Innovation and adoption
Benefit to NHS:
ScanNav increases the efficiency of sonographers and managers in the 20-week FASP anomaly scan by
 
  • Supporting and assisting in the supervision of newly qualified sonographers.
  • Providing oversight of locum sonographers.
  • Performing automated, prospective second trimester anomaly scan audit.
  • Providing real-time support for sonographers.
 
Using ScanNav considerably reduces the effort required to provide comprehensive peer review and oversight of sonographers.

With ScanNav, the sonographer has immediate feedback on any paused image, identifying which criteria are present, and an automatic intelligent checklist that keeps track of progress through the scan. At the end of the scan, the user or their supervisor can see exactly what has been saved, and can comment, or take further action to complete the scan, as appropriate.

Supervisors can, at any time, easily see overall statistics on sonographer performance, enabling them to instantly examine any images where
 
  • The scan is not complete.
  • The sonographer has disagreed with ScanNav (ruling in or out criteria).
  • The sonographer has continued to save images where the view was already complete.

This can help guide training and support. ScanNav fits naturally into the standard workflow to enable time savings. Further efficiency savings are expected to be demonstrated once the initial software rollout start in mid-2017.

For managers, ScanNav® LFR enables automatic 100% audit of FASP 20 week views, something that is currently impractical.
 
Quality goal.

It is also hoped that ScanNav will improve outcomes. A retrospective audit at one NHS trust showed that nearly 50% of scans had at least one missing view. There are many reasons why this might legitimately be the case – e.g. high maternal BMI or unhelpful fetal position, but ScanNav helps to ensure that any views missed are done so explicitly, with reasons for the missing view recorded. This has both quality and medico-legal benefits, allowing compliance with protocol and due diligence to be easily and reliably demonstrated.
Initial Review Rating
3.67 (3 ratings)
Benefit to WM population:
It is well known there is a continued shortage of sonographers. With recruitment being difficult, training and retaining sonographers to reduce reliance on agency workers is the ideal solution, but this inevitably increases pressure on experienced sonographers.

Experienced staff invest a lot of effort and time when training and supporting newly qualified sonographers. Likewise, locum sonographers may require significant supervision from experienced members of the team - adding to an ever-increasing workload. ScanNav will considerably reduce the time needed to provide this support, increasing capacity and reducing costs.

It is also hoped that ScanNav® will improve outcomes. A retrospective audit at one NHS trust showed that nearly 50% of scans had at least one missing view. There are many reasons why this might legitimately be the case – e.g. high maternal BMI or unhelpful fetal position. ScanNav helps to ensure that any views missed are done so explicitly. The live automatic checklist makes it easy to see if any views are still outstanding, and the software will prompt the sonographer to easily record the reason for any missing views at the end of the scan, eliminating accidentally missed views.
Current and planned activity: 
ScanNav has been trained using a team of experienced NHS sonographers and over 370,000 ultrasound images, and tested with 60 professionals across 31 clinical and governance institutions, A prototype has been used at the John Radcliffe in Oxford. A demonstration of the software has been shown to two UK trusts so far, and the sonographers preferred ScanNav to manual peer review.

This demonstration of the software is now available to potential Limited First Release (LFR) partners. We want sites to use the CE marked beta software free of charge to assess utility and report back as part of a post market surveillance exercise.

We would like to work with sites to assess how the software enables them to change practice. As a part of this, we would perform an anonymous analysis of one year’s prior images saved under FASP. A full analysis of the completeness and fitness for purpose would be undertaken, allowing a direct comparison of performance before and after the introduction of ScanNav LFR.
What is the intellectual property status of your innovation?:
IP held by company. Simulator is not applicable to patients. LFR release will hold a medical CE mark.
 
Return on Investment (£ Value): 
N/A
Return on Investment (Timescale): 
N/A
Ease of scalability: 
Simple
Read more
Hide details
Gordon McKenzie 27/03/2017 - 09:22 Publish Login or Register to post comments
5
1
Votes
-99999
Innovation 'Elevator Pitch':
doDOC streamlines collaboration by bringing people and processes together into a single platform, with end-to-end auditability, saving up to 70% in documentation time.
Overview of Innovation:
Life Science and Academic organizations operate in an extremely document-intensive, highly regulated environment. doDOC support this critical process of producing collaborative, compliant, quality documents within tight deadlines.
Whether working with a few individuals or large geographically diverse teams, doDOC makes the co-authoring, review and approval process less painful and more efficient by ensuring neither document quality nor deadlines are compromised in a integrated platform solution.
 
Documentation processes are typically managed in silos by multiple software in each working group of individuals leading to errors, duplicated information and delays, wasting billions of working hours every year.
 
doDOC proposal is simple: a single collaborative platform for the creation of documents with granular control over information processes and a system capable of integrating information from multiple sources avoiding duplication and manual tasks, generating a comprehensive audit trail with measurable effectiveness.


 
How doDOC does that?
1 – Streamlining collaboration and avoiding typical project miscommunication problems;
2 – Automating workflows, ensuring that the right people is doing the right thing in the right moment;
3 – Changing the writing process from a step by step reality to a concurrent and symbiotic experience;
4 – Bringing automation to technical tasks related with document production that until now undermine productivity;
5 – And since doDOC tracks every single event over the entire project, doDOC provides unique insights to allow managers and team members to track progress and access performance in real-time.
 
This change in the technology behind the creation of information allows doDOC users to decrease immensely the total time for the execution of their document-based projects.
 
doDOC Features:
Absolute Security: Full confidentiality, integrity, availability and auditability;
Real-time Collaboration: Collaborate in real-time across departments, regions and organizations.
Automatic Formatting: Full focus on content and automated publishing;
Full Control: Notifications, roles and accesses controlled automatically;
Information Integration: Centralize all records and information in one place;
Custom Workflows: Drive processes automatically and improve efficiency;
Simple Project Management: Optimize virtual teams and operations;
100% Traceability: Provide real-time insight with activity dashboards.

More about doDOC Platform: doDOC Product
More about doDOC: Website
 
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Education, training and future workforce / Wealth creation / Clinical trials and evidence / Innovation and adoption / Patient and medicines safety / Person centred care
Benefit to NHS:
doDOC is a proven cost effective solution for the document co-authoring, review and approval process, providing an excellent return on investment (20X ROI) with both tangible and intangible benefits.
 
Key benefits to NHS by the use of doDOC is the streamlining of cooperation among healthcare professionals with impact on the following areas: patients, processes and knowledge.
 
Improved Patient Care: The complexity of managing patients’ health records requires a cooperative effort that encompasses all of the healthcare professionals involved in their care, each in his/her area of expertise, in order to achieve the best outcomes. doDOC streamlines report generation, focus on the content and decrease the time spent in administrative tasks.
 
Better Process Efficiency: Another variable mentioned when analyzing the usefulness of working together was improving the process. By employing doDOC, the organization is automating the application of standard operational procedures and ensuring compliance with best practices. This improvement in the processes leads to greater efficiency and to an increase in the quality of the healthcare given to the patients.
 
Promoting Knowledge: The importance of collaborative work was also noted for facilitating knowledge among professionals, optimizing time and resources. doDOC allows sharing information in a more effective manner. By controlling information across the network, professionals provide knowledge that is securely shared, with improved health being the result.
Initial Review Rating
3.80 (2 ratings)
Benefit to WM population:
doDOC will promote greater collaboration between the West Midlands Health Organizations: Universities / Hospitals / Companies have with doDOC a single collaborative and secure platform to create value and generate positive impact for the local population.
Current and planned activity: 
doDOC currently works with Top10 Pharmaceutical Companies and world-leading research organizations.
doDOC aims to streamline collaboration across life science and healthcare institutions by simplifying the collaborative effort within document-based projects.
What is the intellectual property status of your innovation?:
Registered Trademark
Trade Secret
Return on Investment (£ Value): 
Very high
Return on Investment (Timescale): 
0-6 mon
Ease of scalability: 
Simple
Read more
Hide details
Carlos Boto 17/03/2017 - 18:33 Publish Login or Register to post comments
0
0
Votes
-99999

Recent Activities

Joanne Mewis commented on Hexitime- The Skill Exchange and Timebank for Improving Healthcare 1 day 4 hours ago
Hexitime- The Skill Exchange and Timebank for Improving Healthcare has been moved from Initial Submission to Publish 1 day 4 hours ago
Helen Hunt commented on MindHarp 1 day 9 hours ago
Sarah Appleby commented on MindHarp 2 days 11 hours ago
Sarah Appleby voted on MindHarp 2 days 11 hours ago

Active Campaigns